Chelsea Therapeutics Presents Data at 14th International Congress on Parkinson's Disease and Movement Disorders
Read more:
http://www.drugs.com/clinical_trials...#ixzz10Ac6FQS2
-- Clinical Review Highlights Neuroprotective Potential of Norepinephrine in Parkinson's Disease -- Northera, an Orally Available Norepinephrine Pro-drug, Significantly Improves Symptoms of Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease -- Over 25 Years of Research Support
Cardiovascular Safety of Northera in Patient Population Characterized by Advanced Age and Significant Co-Morbidities
Read more:
http://www.drugs.com/clinical_trials...#ixzz10AZyEMQd
Chelsea Therapeutics Soars As Parkinson's Study Successful
must subscribe
http://online.wsj.com/article/BT-CO-...20-703879.html